Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL744384 | 0.86 | LIPE (0.62) | LIPEEGLN1 | |
| SCHEMBL336236 | 0.85 | LIPE (0.55) | LIPE | |
| SCHEMBL336840 | 0.83 | LIPE (0.44) | LIPEEGLN1 | |
| SCHEMBL10241 | 0.80 | LIPE (0.63) | LIPEEGLN1 | |
| SCHEMBL11435 | 0.78 | LIPE (0.73) | LIPE | |
| SCHEMBL12702054 | 0.78 | LIPE (0.73) | LIPE | |
| SCHEMBL1589124 | 0.78 | LIPE (0.73) | LIPE | |
| SCHEMBL10471 | 0.78 | LIPE (0.61) | LIPEEGLN1 | |
| SCHEMBL1588877 | 0.77 | LIPE (0.62) | LIPE | |
| SCHEMBL11640 | 0.77 | LIPE (0.60) | LIPEEGLN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2558464-B1 | AZACYCLIC SPIRODERIVATIVES AS HSL INHIBITORS | HOFFMANN LA ROCHE (CH) | 2014-06-18 | — | — | EP | disclosed |
| EP-2558464-A1 | AZACYCLIC SPIRODERIVATIVES AS HSL INHIBITORS | F. Hoffmann-La Roche AG (CH) | 2013-02-20 | — | — | EP | disclosed |
| US-8097634-B2 | Azacyclic derivatives | HOFFMANN-LA ROCHE INC. (US) | 2012-01-17 | — | — | US | disclosed |
| US-8097634-B2 | Azacyclic derivatives | HOFFMANN-LA ROCHE INC. (US) | 2012-01-17 | — | — | US | disclosed |
| US-8097634-B2 | Azacyclic derivatives | HOFFMANN-LA ROCHE INC. (US) | 2012-01-17 | — | — | US | disclosed |
| WO-2011128316-A1 | AZACYCLIC SPIRODERIVATIVES AS HSL INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2011-10-20 | — | — | WO | disclosed |
| US-20110257212-A1 | NEW AZACYCLIC DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2011-10-20 | — | — | US | disclosed |
| US-20110257212-A1 | NEW AZACYCLIC DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2011-10-20 | — | — | US | disclosed |
| US-20110257212-A1 | NEW AZACYCLIC DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2011-10-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110257212-A1 | NEW AZACYCLIC DERIVATIVES | LIPE, GPR119, LPL | LIPE 1/4885EGLN1 834/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.